Angiotensin IV and analogs as regulators of fibrinolysis

Details Angiotensin IV and analogs as regulators of fibrinolysis Angiotensin IV and analogs as regulators of fibrinolysis

1993-08-27

1997-02-04

Knode, Marian C.

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

435 721, 435 792, C12Q 168, G01N 33567, G01N 3353

Patent

active

055996639

ABSTRACT:
Angiotensin IV (VAL-TYR-ILE-HIS-PRO-PHE), a degradation product of angiotensin II previously thought to be inactive, interacts directly with endothelial cells to induce expression of PAI-1 and thereby to inhibit clot lysis attributable to endogenous t-PA. Moreover, angiotensin IV does not effect substantial physiological changes (vasoconstriction, increased blood pressure, etc.) characteristic of angiotensin II. Fibrinolysis is promoted by reducing the amount or the effect of angiotensin IV. Fibrinolysis is inhibited by providing enhanced angiotensin IV. Methods of screening candidates for antagonizing angiotensin IV are also disclosed.

REFERENCES:
Gelehrter et al., J. Clin. Invest. 77:165-169, 1986.
Dichek et al., Blood 74:222-228, 1989.
Gavras et al., Lancet 19-22, 1971.
Gavras, H., Hypertension 23:813-818, 1994.
Olson et al., Proc. Natl. Acad. Sci. USA 88:1928-1932, 1991.
Ridker et al., Circulation 87:1969-1973, 1993.
Wright et al., J. Am. Coll. Cardiol. 24:67-73, 1994.
van Leeuwen et al., Circulation 90:362-368, 1994.
Vaughan et al., J. Clin. Invest. 95:995-1001, 1995.
Harding et al., Brain Res. 583:340-343, 1992.
Miller-Wing et al., FASEB 6:3708 Abstract, 1992.
Chaki et al., FASEB 6:3705 Abstract, 1992.
Swanson et al., FASEB 6:3706 Abstract, 1992.
Jarvis et al., Eur. J. Pharm. 219:319-322, 1992.
Sardinia et al., Peptides 15:1399-1406, 1994.
Hall et al., Reg. Peptides 44:225-232, 1993.
Hanesworth et al., J. Pharm. Exptl. Ther. 266:1306-1042, 1993.
Swanson et al., Reg. Peptides 40:409-419, 1992.
Bumpus et al., Biochem. Biophys. Acta 46:38-44, 1961.
Regoli et al., Pharmacol. Reviews 26:69-123, 1974.
Bennett et al., J. Biol. Chem. 251:7423-7430, 1976.
Fitzsimons, J. T., J. Physiol. Lond. 214:295-303.
Tonnaer et al., Brain Res. 236:417-428, 1982.
Siemens et al., Neurochem 57:690-700, 1991.
Kono et al., Acta Endocr. 99:577-584, 1982.
Kono et al., Acta Endocr. 109:249-253, 1985.
Haberl et al., Circ. Res. 68:1621-1627, 1991.
Brazsko et al., Brain Res. 542:49-54, 1991.
Brazsko et al., Neuroscience 27:777-783, 1988.
Brazsko et al., Behav. Brain Res. 25:195-203, 1987.
Semple et al., Circ. Res. 39:671-678, 1976.
Blumberg et al., Circ. Res. 41:154-158, 1977.
Sardinia et al, FASEB, 57(3-4), A437, 1993 (Presented Mar. 28-Apr. 1993).

Affiliated with

Also associated with

Rating

Angiotensin IV and analogs as regulators of fibrinolysis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Angiotensin IV and analogs as regulators of fibrinolysis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiotensin IV and analogs as regulators of fibrinolysis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-677385